Asunto(s)
Alopecia , Liquen Plano , Alopecia/diagnóstico , Fibrosis , Humanos , Liquen Plano/diagnóstico , Londres , MasculinoAsunto(s)
Dermatitis Atópica , Eccema , Psoriasis , Biomarcadores , Estudios de Cohortes , Dermatitis Atópica/diagnóstico , Humanos , Psoriasis/diagnósticoAsunto(s)
COVID-19 , Psoriasis , Estudios Transversales , Humanos , Pandemias , Psoriasis/epidemiología , SARS-CoV-2RESUMEN
BACKGROUND: The effectiveness and cost-effectiveness of biologic therapies for psoriasis are significantly compromised by variable treatment responses. Thus, more precise management of psoriasis is needed. OBJECTIVES: To identify subgroups of patients with psoriasis treated with biologic therapies, based on changes in their disease activity over time, that may better inform patient management. METHODS: We applied latent class mixed modelling to identify trajectory-based patient subgroups from longitudinal, routine clinical data on disease severity, as measured by the Psoriasis Area and Severity Index (PASI), from 3546 patients in the British Association of Dermatologists Biologics and Immunomodulators Register, as well as in an independent cohort of 2889 patients pooled across four clinical trials. RESULTS: We discovered four discrete classes of global response trajectories, each characterized in terms of time to response, size of effect and relapse. Each class was associated with differing clinical characteristics, e.g. body mass index, baseline PASI and prevalence of different manifestations. The results were verified in a second cohort of clinical trial participants, where similar trajectories following the initiation of biologic therapy were identified. Further, we found differential associations of the genetic marker HLA-C*06:02 between our registry-identified trajectories. CONCLUSIONS: These subgroups, defined by change in disease over time, may be indicative of distinct endotypes driven by different biological mechanisms and may help inform the management of patients with psoriasis. Future work will aim to further delineate these mechanisms by extensively characterizing the subgroups with additional molecular and pharmacological data.
Asunto(s)
Productos Biológicos , Psoriasis , Factores Biológicos/uso terapéutico , Productos Biológicos/uso terapéutico , Terapia Biológica , Ensayos Clínicos como Asunto , Humanos , Factores Inmunológicos , Psoriasis/tratamiento farmacológico , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
BACKGROUND: Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatments. OBJECTIVES: We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation. METHODS: Online surveys were completed by individuals with psoriasis (globally) or rheumatic and musculoskeletal diseases (RMDs) (UK only) between 4 May and 7 September 2020. We used multiple logistic regression to assess the association between treatment type and risk-mitigating behaviour, adjusting for clinical and demographic characteristics. We characterized international variation in a mixed-effects model. RESULTS: Of 3720 participants (2869 psoriasis, 851 RMDs) from 74 countries, 2262 (60·8%) reported the most stringent risk-mitigating behaviour (classified here under the umbrella term 'shielding'). A greater proportion of those receiving targeted therapies (biologics and Janus Kinase inhibitors) reported shielding compared with those receiving no systemic therapy [adjusted odds ratio (OR) 1·63, 95% confidence interval (CI) 1·35-1·97]. The association between targeted therapy and shielding was preserved when standard systemic therapy was used as the reference group (OR 1·39, 95% CI 1·23-1·56). Shielding was associated with established risk factors for severe COVID-19 [male sex (OR 1·14, 95% CI 1·05-1·24), obesity (OR 1·37, 95% CI 1·23-1·54), comorbidity burden (OR 1·43, 95% CI 1·15-1·78)], a primary indication of RMDs (OR 1·37, 95% CI 1·27-1·48) and a positive anxiety or depression screen (OR 1·57, 95% CI 1·36-1·80). Modest differences in the proportion shielding were observed across nations. CONCLUSIONS: Greater risk-mitigating behaviour among people with IMIDs receiving targeted therapies may contribute to the reported lower risk of adverse COVID-19 outcomes. The behaviour variation across treatment groups, IMIDs and nations reinforces the need for clear evidence-based patient communication on risk-mitigation strategies and may help inform updated public health guidelines as the pandemic continues.
Asunto(s)
COVID-19 , Artropatías , Estudios Transversales , Humanos , Masculino , Pandemias , SARS-CoV-2Asunto(s)
Alopecia , Liquen Plano , Alopecia/epidemiología , Estudios Transversales , Femenino , Fibrosis , Humanos , Reino Unido/epidemiologíaAsunto(s)
Betacoronavirus/inmunología , Infecciones por Coronavirus/epidemiología , Dermatitis Atópica/inmunología , Carga Global de Enfermedades/estadística & datos numéricos , Neumonía Viral/epidemiología , Psoriasis/inmunología , Betacoronavirus/aislamiento & purificación , COVID-19 , Infecciones por Coronavirus/inmunología , Infecciones por Coronavirus/terapia , Infecciones por Coronavirus/virología , Conjuntos de Datos como Asunto , Dermatitis Atópica/tratamiento farmacológico , Humanos , Factores Inmunológicos/uso terapéutico , Cooperación Internacional , Estudios Observacionales como Asunto , Pandemias , Medición de Resultados Informados por el Paciente , Neumonía Viral/inmunología , Neumonía Viral/terapia , Neumonía Viral/virología , Psoriasis/tratamiento farmacológico , Sistema de Registros/estadística & datos numéricos , SARS-CoV-2 , Resultado del TratamientoRESUMEN
BACKGROUND: The 'treat to target' paradigm improves outcomes and reduces costs in chronic disease management but is not yet established in psoriasis. OBJECTIVES: To identify treatment targets in psoriasis using two common measures of disease activity: Psoriasis Area and Severity Index (PASI) and Physician's Global Assessment (PGA). METHODS: Data from a multicentre longitudinal U.K. cohort of patients with psoriasis receiving systemic or biologic therapies (British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR) were used to identify absolute PASI thresholds for 90% (PASI 90) and 75% (PASI 75) improvements in baseline disease activity, using receiver operating characteristic curves. The relationship between PGA (clear, almost clear, mild, moderate, moderate-severe, severe) and PASI (range 0-72) was described, and the concordance between absolute and relative definitions of response was determined. The same approach was used to establish treatment response and eligibility definitions based on PGA. RESULTS: Data from 13 422 patients were available (58% male, 91% white ethnicity, mean age 44·9 years), including over 23 000 longitudinal PASI and PGA scores. An absolute PASI ≤ 2 was concordant with PASI 90 and an absolute PASI ≤ 4 was concordant with PASI 75 in 90% and 88% of cases, respectively. These findings were robust to subgroups of timing of assessment, baseline disease severity and treatment modality. PASI and PGA were strongly correlated (Spearman's rank correlation coefficient 0·92). The median PASI increased from 0 (interquartile range 0-0, range 0-23) to 19 (interquartile range 15-25, range 0-64) for PGA clear to severe, respectively. PGA clear/almost clear was concordant with PASI ≤ 2 in 90% of cases, and PGA moderate-severe severe was concordant with the National Institute for Health and Care Excellence PASI eligibility criteria for biologics in 81% of cases. CONCLUSIONS: An absolute PASI ≤ 2 and PGA clear/almost clear represent relevant disease end points to inform treat-to-target management strategies in psoriasis. What's already known about this topic? The most commonly used relative disease activity measure in psoriasis is ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90); however, it has several limitations including dependency on a baseline severity assessment. Defining an absolute target disease activity end point in psoriasis has the potential to improve patient outcomes and reduce costs, as demonstrated by treat-to-target approaches in other chronic diseases such as hypertension and diabetes. The Physician's Global Assessment (PGA) is a popular alternative measure of psoriasis severity in daily practice; however, its utility has not been formally assessed with respect to PASI. What does this study add? An absolute PASI ≤ 2 corresponds with PASI 90 response and is a relevant disease end point for treat-to-target approaches in psoriasis. There is a strong correlation between PASI and PGA. PGA moderate-severe/severe may serve as an alternative eligibility criterion for biologics to PASI-based definitions, and PGA clear/almost clear is an appropriate alternative absolute treatment end point. What are the clinical implications of this work? Absolute PASI ≤ 2 and PGA clear/almost clear represent relevant disease end points to inform treat-to-target management strategies in psoriasis.
Asunto(s)
Productos Biológicos , Psoriasis , Adulto , Productos Biológicos/uso terapéutico , Estudios de Cohortes , Dermatólogos , Etnicidad , Femenino , Humanos , Factores Inmunológicos , Masculino , Persona de Mediana Edad , Psoriasis/tratamiento farmacológico , Índice de Severidad de la Enfermedad , Resultado del TratamientoAsunto(s)
Captopril/síntesis química , Química Farmacéutica/métodos , Fármacos Gastrointestinales/síntesis química , Captopril/administración & dosificación , Captopril/farmacocinética , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/síntesis química , Preparaciones de Acción Retardada/farmacocinética , Formas de Dosificación , Fármacos Gastrointestinales/administración & dosificación , Fármacos Gastrointestinales/farmacocinéticaRESUMEN
Novel drug delivery systems are one of the widely used delivery systems. In the present scenario, amongst them, "Drug Loaded Erythrocytes" is one of the growing and potential systems for delivery of drugs and enzymes. Erythrocytes are biocompatible, biodegradable, possess long circulation half-life and can be loaded with variety of biologically active substances. Carrier erythrocytes are prepared by collecting blood sample from the organism of interest and separating erythrocytes from plasma. By using various physical and chemical methods the cells are broken and the drug is entrapped into the erythrocytes, finally they are resealed and the resultant carriers are then called "resealed erythrocytes". Surface modification with glutaraldehyde, antibodies, carbohydrates like sialic acid and biotinylation of loaded erythrocytes (biotinylated erythrocytes) is possible to improve their target specificity and to increase their circulation half-life. Upon reinjection the drug loaded erythrocytes serve as slow circulation depots, targets the drug to the reticuloendothelial system (RES), prevents degradation of loaded drug from inactivation by endogenous chemicals, attain steady state concentration of drug and decrease the side-effects of loaded drug. Nowadays, Nanoerythrosomes based drug delivery systems have excellent potential for clinical application.